(Q34185007)

31 July 2017

1 reference

title

Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies (English)

1 reference

Apostolia Maria Tsimberidou

31 July 2017

author

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

31 July 2017

Yesid Alvarado

2

1 reference

31 July 2017

Francis J Giles

series ordinal

3

1 reference

31 July 2017

publication date

1 August 2002

1 reference

Expert Review of Anticancer Therapy

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

437-448

1 reference

DNA precursor asymmetries, replication fidelity, and variable genome evolution

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Reduction of Ribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Functional regulation of mammalian ribonucleotide reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Ribonucleotide reductase as a chemotherapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Pharmacokinetics and pharmacodynamics of hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Gemcitabine in non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Gemcitabine for relapsed or resistant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.437

21 January 2018

Identifiers

DOI

10.1586/14737140.2.4.437

1 reference

31 July 2017

1 reference